ES2311544T3 - Imidazoles sustituidos como agonistas o antagonistas duales de histamina h1 y h3. - Google Patents

Imidazoles sustituidos como agonistas o antagonistas duales de histamina h1 y h3. Download PDF

Info

Publication number
ES2311544T3
ES2311544T3 ES01971115T ES01971115T ES2311544T3 ES 2311544 T3 ES2311544 T3 ES 2311544T3 ES 01971115 T ES01971115 T ES 01971115T ES 01971115 T ES01971115 T ES 01971115T ES 2311544 T3 ES2311544 T3 ES 2311544T3
Authority
ES
Spain
Prior art keywords
group
alkyl
imidazols
histamine
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01971115T
Other languages
English (en)
Inventor
Neng-Yang Shih
Robert G Aslanian
John J Piwinski
Andrew T Lupo Jr
Adriano Afonso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2311544T3 publication Critical patent/ES2311544T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Un compuesto que incluye sus enantiómeros estereoisómeros y tautómeros, o sales o solvatos farmacéuticamente aceptables de dicho compuesto, en donde dicho compuesto tiene la estructura general que se muestra en la Fórmula I: (Ver fórmula) en donde G se selecciona del grupo que consiste en -(CH2)v-NR 3 -, -(CH2)v-O-, (CH2)v-S(O)2-, -(CH2)v-NR 3 -C(NR 4 )-NR 3 -, -(CH2)v-O-C(O)NR 3 -, -(CH2)v-NR 3 C(O)NR 3 -, -(CH2)v-NR 3 C(O)O-, -(CH2)v-NR 3 C(O)- o -(CH2)vC(O)NR 3 ; M es un grupo alquilo C1-C6, o un grupo alquenilo C2-C6; X e Y se seleccionan independientemente del grupo que consiste en N, CH o N-óxido; R 1 y R 2 pueden ser cada uno los números 1-4 y se seleccionan independientemente del grupo que consiste en H, halógeno, alquilo C1-C6, alcoxi C1-C6, polihalo alcoxi C1-C6, OH, CF3, NH2, NHC(O)alquilo, CN o NO2; R 3 se selecciona independientemente del grupo que consiste en H, alquilo C1-C6, fenilo sustituido o no sustituido, bencilo sustituido o no sustituido de la fórmula: (Ver fórmula) R 4 se selecciona del grupo que consiste en H, CN ó CO2R 5 ; R 5 se selecciona del grupo que consiste en alquilo C1-C6 y bencilo sustituido o no sustituido; R 6 se selecciona del grupo que consiste en H o alquilo C1-C6; q es 2-5; v es 0-6; y z es 0, 1 ó 2.
ES01971115T 2000-09-20 2001-09-18 Imidazoles sustituidos como agonistas o antagonistas duales de histamina h1 y h3. Expired - Lifetime ES2311544T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23403800P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
ES2311544T3 true ES2311544T3 (es) 2009-02-16

Family

ID=22879621

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01971115T Expired - Lifetime ES2311544T3 (es) 2000-09-20 2001-09-18 Imidazoles sustituidos como agonistas o antagonistas duales de histamina h1 y h3.

Country Status (14)

Country Link
US (1) US6528522B2 (es)
EP (1) EP1318993B1 (es)
JP (1) JP2004509869A (es)
CN (1) CN1558907A (es)
AR (1) AR031612A1 (es)
AT (1) ATE405557T1 (es)
AU (1) AU2001291040A1 (es)
CA (1) CA2422210C (es)
DE (1) DE60135471D1 (es)
ES (1) ES2311544T3 (es)
HK (1) HK1052180A1 (es)
MX (1) MXPA03002445A (es)
MY (1) MY120281A (es)
WO (1) WO2002024657A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9796717B2 (en) * 2013-02-19 2017-10-24 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349943A (zh) 2015-09-09 2018-07-31 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
ES2058651T3 (es) 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
CA2125964C (en) 1991-12-18 2001-06-19 Neng-Yang Shih Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
ZA985410B (en) 1997-06-24 1999-01-04 Novo Nordisk As Use of somatostatin agonists and antagonists for treating diseases related to the eye
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses

Also Published As

Publication number Publication date
MXPA03002445A (es) 2003-06-19
DE60135471D1 (de) 2008-10-02
AR031612A1 (es) 2003-09-24
AU2001291040A1 (en) 2002-04-02
CA2422210C (en) 2009-10-27
US6528522B2 (en) 2003-03-04
CA2422210A1 (en) 2002-03-28
US20020082272A1 (en) 2002-06-27
EP1318993A2 (en) 2003-06-18
JP2004509869A (ja) 2004-04-02
CN1558907A (zh) 2004-12-29
ATE405557T1 (de) 2008-09-15
WO2002024657A2 (en) 2002-03-28
EP1318993B1 (en) 2008-08-20
WO2002024657A3 (en) 2002-07-11
HK1052180A1 (zh) 2003-09-05
MY120281A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
AR121419A1 (es) Piridazinonas como inhibidoras de parp7
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
AR104716A1 (es) Agonistas de triazol del receptor apj
AR051387A1 (es) Analogos de anilino-pirimidina
PE20040835A1 (es) Administracion combinada de una indolina con un agente quimioterapeutico para transtornos de proliferacion celular
BRPI0519288A2 (pt) compostos heterocÍclicos como antagonistas de ccr2b
CR8264A (es) Derivados de malonamida bloqueadores de la actividad gamma-secretase
CO6190611A2 (es) Derivados de espirocromanona sustituidos
PE20060286A1 (es) Derivados de piperidina o piperazina como antagonistas del receptor cgrp
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
DE69527405T2 (de) Antivirale Ether von Aspartat-Protease-Substrat-Isosteren
WO2006109075A3 (en) Hydroxybenzamide derivatives and their use as inhibitors of hsp90
EA200300777A1 (ru) N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов для fsad
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20090444A1 (es) Eteres heterociclicos sustituidos y su uso en trastornos del snc
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
AR026352A1 (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.
ES2311544T3 (es) Imidazoles sustituidos como agonistas o antagonistas duales de histamina h1 y h3.
CO5660290A2 (es) 6-(1,1-difluoroalquil)-4-aminopicolinatos y su uso como herbicidas
RS51126B (sr) Postupak za pripremanje mezilata piperazin derivata
WO2004020584A3 (en) Antagonists of chemokine receptors
CO5660258A2 (es) Derivados de imidazol iii
AR120452A1 (es) Compuestos heterocíclicos y usos de los mismos
DK1299388T3 (da) Variolin-derivater som anti-cancermidler
PL1692098T3 (pl) Pochodna alfa-ketomidu oraz sposób jej wytwarzania i zastosowanie